Neurocrine biosciences announces u.s. fda accepts supplemental new drug application for valbenazine as a treatment for chorea associated with huntington disease

Prescription drug user fee act (pdufa) target action date set for august 20, 2023 san diego , dec. 22, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), a leading neuroscience-focused biopharmaceutical company, today announced that the u.s. food and drug administration (fda) has accepted its supplemental new drug application (snda) for valbenazine as a treatment for chorea associated with huntington disease (hd). the agency set a prescription drug user fee act (pdufa) target action date of august 20, 2023.
NBIX Ratings Summary
NBIX Quant Ranking